AKB-9778
Phase 2Small molecule
AKB-9778 is one of 38 small molecule programs targeting Diabetic Macular Edema. It is currently in Phase 2.
2
Indications
6
Total Trials
0
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
180 competitors in Diabetic Macular Edema
#DrugCompanyPhaseTrials
1Eylea
RegeneronPhase 3
Lucentis
RochePhase 3
Avastin
BBio-Thera Solutions
Phase 3
Beovu
NovartisPhase 3
Kenalog
BBausch Health Americas, Inc.
Phase 3
Synalar
EEurofarma Laboratorios S.A.
Phase 3
Lucentis
NovartisPhase 3
Luye Pharma Conbercept
CChengdu Kanghong Biotech Co., Ltd.
Phase 3
Glucophage
EMD SeronoPhase 3
Intravitreal Ranibizumab
RochePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Diabetic Macular Edema2 trials
Absorption1 trial
Tics1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AKB-9778. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- AAerpio Therapeutics